 This research paper examines the effectiveness of combining two different types of drugs to treat hepatitis C virus, HCV. It looks at the sterile pathway, which is involved in cholesterol production, and the protein-prenylation pathway, which is involved in protein modification. By combining these two pathways, the researchers were able to identify new targets for HCV treatment. They found that certain combinations of drugs could produce strong synergy, meaning that the combined effect was greater than the sum of its parts. This suggests that this approach may be more effective than using one drug alone. Additionally, they discovered that the combination of drugs had minimal side effects, suggesting that it would be safe to use in humans. This article was authored by Christopher M. Owens, Cristina Mowany, Jill M. Graney, and others.